AustriaAustria

Bioethical PID Report

06.08.2004

Vienna - In its recently presented report on pre-implantation diagnostics (PID) the Bioethics Commission at the Austrian Federal Chancellery deliberately avoided a decision on a particular option. “This should rather be the result of the political process and the work of legislature. The Bioethics Commission however reviewed and presented all parties' arguments in the current debate,” said chairman Prof. Dr. Johannes Huber. While the 19 commission members unanimously agreed on the scientific-medical aspects, areas of ethical and legal applicability as well as the different legal options, they also expressly pointed out that this does not represent an unconditional recommendation for PID - conversely a total ban is neither ethically nor legally acceptable.
According to renowned legal experts the current Reproductive Medicines Law provides sufficient scope for the research on and the treatment of so-called “cells that are capable to develop” to a degree, which according to the current state of medical sciences and experience are necessary to induce pregnancy. Thus PID would presently be acceptable and legal if the embryos concerned had a limited life expectancy due to chromosomal abnormalities or other genetic malfunctions. Within this tight framework PID would also be ethically acceptable. Seven members that opt for maintaining the current legal status prefer the limitation of PID to these extreme cases of “non-viable” embryos within the current legislation on in vitro-fertilisation. The other twelve members recommended to extend applicability of PID in certain cases to couples that are under high risk to get children with severe genetically determined diseases - including the determination of the disease-related sex. General genetic screening or PID as means for positive selection for desirable features received outright rejected from the commission.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/bioethical-pid-report.html

Product of the week

Products

Events

All Events

Current issue

All issues